Fry William H D, Kotelawala Lakmal, Sweeney Colleen, Carraway Kermit L
UC Davis Cancer Center, Research Building III, Rm 1100B, 4645 2nd Avenue, Sacramento, California 95817, USA.
Exp Cell Res. 2009 Feb 15;315(4):697-706. doi: 10.1016/j.yexcr.2008.07.022. Epub 2008 Jul 31.
The ErbB family of receptor tyrosine kinases engages a wide variety of signaling pathways that collectively direct transcriptional programs controlling organogenesis during development and tissue maintenance in the adult. These receptors are also frequently found overexpressed or aberrantly activated in various cancers, suggesting that ErbB receptor signaling activity must be very tightly regulated. Sufficient levels of ErbB signaling are necessary to mediate tissue homeostasis, for example, but over-signaling can trigger cellular processes that contribute to cancer initiation or progression. Efforts over the last quarter century have led to a thorough understanding of the signaling pathways that are activated by these receptors and the mechanisms by which ErbB receptors engage these pathways. However, the compensatory negative regulatory mechanisms responsible for attenuating receptor activation have only more recently begun to be explored. Here we review the different known mechanisms of ErbB negative regulation, with particular emphasis on those proteins that exhibit some specificity for the ErbB family. We also describe how loss or suppression of ErbB negative regulators may contribute to tumor development, and discuss how restoration or augmentation of these pathways may represent a novel avenue for the development of ErbB-targeted therapies.
受体酪氨酸激酶的表皮生长因子受体(ErbB)家族参与多种信号通路,这些信号通路共同指导转录程序,控制发育过程中的器官形成以及成体中的组织维持。这些受体在各种癌症中也经常被发现过度表达或异常激活,这表明ErbB受体信号活性必须受到非常严格的调控。例如,足够水平的ErbB信号对于介导组织稳态是必要的,但过度信号传导会触发有助于癌症起始或进展的细胞过程。在过去的四分之一个世纪里,人们对这些受体激活的信号通路以及ErbB受体参与这些通路的机制有了透彻的了解。然而,负责减弱受体激活的补偿性负调控机制直到最近才开始被探索。在这里,我们回顾了已知的ErbB负调控的不同机制,特别强调那些对ErbB家族表现出一定特异性的蛋白质。我们还描述了ErbB负调控因子的缺失或抑制如何可能导致肿瘤发展,并讨论了这些通路的恢复或增强如何可能代表一种开发针对ErbB的治疗方法的新途径。